CL2024002306A1 - Elementos reguladores de gjb2 y usos de los mismos. - Google Patents

Elementos reguladores de gjb2 y usos de los mismos.

Info

Publication number
CL2024002306A1
CL2024002306A1 CL2024002306A CL2024002306A CL2024002306A1 CL 2024002306 A1 CL2024002306 A1 CL 2024002306A1 CL 2024002306 A CL2024002306 A CL 2024002306A CL 2024002306 A CL2024002306 A CL 2024002306A CL 2024002306 A1 CL2024002306 A1 CL 2024002306A1
Authority
CL
Chile
Prior art keywords
gjb2
promoters
hearing loss
regulatory elements
enhancers
Prior art date
Application number
CL2024002306A
Other languages
English (en)
Spanish (es)
Inventor
Burns Joseph
Gibson Tyler
Sabin Leah
Ellis Kathryn
LEBO Kevin
Pregernig Gabriela
Drummond Samuelson Meghan
CANCELARICH Sarah
DI BATTISTA MIANI Daniela
Original Assignee
Decibel Therapeutics Inc
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decibel Therapeutics Inc, Regeneron Pharma filed Critical Decibel Therapeutics Inc
Publication of CL2024002306A1 publication Critical patent/CL2024002306A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2024002306A 2022-02-04 2024-07-31 Elementos reguladores de gjb2 y usos de los mismos. CL2024002306A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306941P 2022-02-04 2022-02-04
US202263306928P 2022-02-04 2022-02-04

Publications (1)

Publication Number Publication Date
CL2024002306A1 true CL2024002306A1 (es) 2024-12-27

Family

ID=87552983

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002306A CL2024002306A1 (es) 2022-02-04 2024-07-31 Elementos reguladores de gjb2 y usos de los mismos.

Country Status (11)

Country Link
US (1) US20250127928A1 (cg-RX-API-DMAC10.html)
EP (1) EP4473005A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025506419A (cg-RX-API-DMAC10.html)
KR (1) KR20240156606A (cg-RX-API-DMAC10.html)
AU (1) AU2023214481A1 (cg-RX-API-DMAC10.html)
CA (1) CA3250345A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002306A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024012057A2 (cg-RX-API-DMAC10.html)
IL (1) IL314705A (cg-RX-API-DMAC10.html)
MX (1) MX2024009520A (cg-RX-API-DMAC10.html)
WO (1) WO2023150689A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260027327A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Otic drug delivery system and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI896570B (zh) * 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
CN116096900A (zh) * 2020-05-13 2023-05-09 阿库斯股份有限公司 用于治疗gjb2相关听力损失的组合物和方法

Also Published As

Publication number Publication date
KR20240156606A (ko) 2024-10-30
MX2024009520A (es) 2024-09-11
EP4473005A2 (en) 2024-12-11
US20250127928A1 (en) 2025-04-24
WO2023150689A3 (en) 2023-11-16
JP2025506419A (ja) 2025-03-11
IL314705A (en) 2024-10-01
CA3250345A1 (en) 2023-08-10
WO2023150689A8 (en) 2023-10-12
EP4473005A4 (en) 2026-02-18
CO2024012057A2 (es) 2024-09-30
WO2023150689A2 (en) 2023-08-10
AU2023214481A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
CL2023000294A1 (es) Expresión selectiva de un transgene de tejidos
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
CY1125196T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
CO2020010376A2 (es) Uso de vectores lentivirales que expresan el factor viii
CO2023016804A2 (es) Composiciones y métodos para el tratamiento de la pérdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de estereocilina
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
MX2022003063A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
CO2021006060A2 (es) Generación de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitución de genes dirigida al hígado
MX2022001202A (es) Ratones con genes insertados de sirp¿-il15 humanizadas y métodos para usarlos.
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
PT3793573T (pt) Subconjuntos de células natural killer humanas que apresentam respostas imunitárias dirigidas por anticorpos melhoradas
CO2017013432A2 (es) Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones
MX2021000858A (es) Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
BR112021017853A2 (pt) Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii
PE20190335A1 (es) Receptores de celulas t
MX2021011037A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos de fenilalanina hidroxilasa (pah).
DOP2017000094A (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
RU2017111300A (ru) Центральные т-клетки памяти для адоптивной т-клеточной терапии
MX2019008755A (es) Variantes de hsd17b13 y usos de las mismas.
MX2018001529A (es) Animales resistentes a patogenos que tienen genes cd163 modificados.
MX2019006722A (es) Construcciones de adenovirus de chimpance con antigenos de lyssavirus.
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
CO2024012057A2 (es) Elementos reguladores de gjb2 y usos de los mismos
MX2025006880A (es) Metodos para generar celulas madre hematopoyeticas
MX2018006373A (es) Produccion de virus en cultivos celulares.